<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03771612</url>
  </required_header>
  <id_info>
    <org_study_id>IDL</org_study_id>
    <nct_id>NCT03771612</nct_id>
  </id_info>
  <brief_title>Inflammation and Daily Life Study</brief_title>
  <official_title>Inflammation and Daily Life Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      UCLA researchers looking for healthy individuals (age 45-60) to participate in a study&#xD;
      investigating whether an anti-inflammatory medication can impact daily life experiences.&#xD;
&#xD;
      Everyday for four weeks, participants will take either an anti-inflammatory medication&#xD;
      (naproxen) twice daily, or a placebo pill twice daily. Participants will also answer daily&#xD;
      questions during the 2-week period. Participants will also fill out questionnaires and&#xD;
      complete a few tasks on the computer: once prior to the 2-week period and once immediately&#xD;
      after the 2-week period, both during online study sessions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants (ntotal=50) will be men and women, ages 45-60. All interested participants will&#xD;
      first complete a structured telephone interview in order to assess eligibility.&#xD;
&#xD;
      The study will begin with filling out questionnaires, as well as an online session to&#xD;
      complete some tasks. You will then be randomly assigned to take either an anti-inflammatory&#xD;
      medication (naproxen) or placebo (inactive substance) to take twice daily everyday for the&#xD;
      following two weeks. You will also be contacted by text message to remind you to take your&#xD;
      pills, to ask if you have taken your pills, and to send you a link to fill out questionnaires&#xD;
      once daily. After the two weeks are over, you will again complete questionnaires and the&#xD;
      online study session with tasks. Finally, two weeks after the second session, you will&#xD;
      receive an email to fill out questionnaires online.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported health</measure>
    <time_frame>Baseline (Week 1 of study), post-intervention (Week 4 of study)</time_frame>
    <description>Changes in self-report measures of health</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep</measure>
    <time_frame>Baseline (Week 1 of study), post-intervention (Week 4 of study)</time_frame>
    <description>Changes in sleep (using the Insomnia Severity Index)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline (Week 1 of study), post-intervention (Week 4 of study)</time_frame>
    <description>Changes in depression (using the Beck Depression Inventory)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Picture viewing task</measure>
    <time_frame>Baseline (Week 1 of study), post-intervention (Week 4 of study)</time_frame>
    <description>Changes in responses (intensity and valance) of ratings of pictures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monetary reward task</measure>
    <time_frame>Baseline (Week 1 of study), post-intervention (Week 4 of study)</time_frame>
    <description>Changes in reaction time to potentially winning money in a task</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Half of the participants will be randomly assigned to receive a placebo pill twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy adults 45-60&#xD;
&#xD;
        Exclusion Criteria: Following a structured telephone interview, participants with the&#xD;
        following conditions will not be able to participate:&#xD;
&#xD;
          -  certain active, uncontrolled medical disorders&#xD;
&#xD;
          -  use of certain medications (e.g., hypnotic and psychotropic medication, steroid use,&#xD;
             opioid use)&#xD;
&#xD;
          -  psychiatric disorders (e.g., current major depression, bipolar disorder)&#xD;
&#xD;
        Other exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi I Eisenberger, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Hazlett, M.A.</last_name>
    <phone>310-267-5196</phone>
    <email>ucla.inflammation.study@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Department of Psychology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Naomi Eisenberger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Immune system</keyword>
  <keyword>Social psychology</keyword>
  <keyword>Health psychology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

